Extension Study of BG00012 in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)
Status:
Completed
Trial end date:
2018-09-24
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to evaluate the long-term safety of BG00012 in subjects
who completed Study 109MS202 (NCT02410200). Secondary objectives are as follows: To evaluate
the long-term efficacy of BG00012 and to describe the long-term Multiple Sclerosis (MS)
outcomes in subjects who completed Study 109MS202 (NCT02410200).